A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated With Mild to Moderate Alzheimer's Disease (MINDSET 2)
Latest Information Update: 23 Oct 2025
At a glance
- Drugs Trospium chloride/xanomeline (Primary) ; Xanomeline (Primary)
- Indications Alzheimer's disease
- Focus Registrational; Therapeutic Use
- Acronyms MINDSET 2
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 20 Aug 2025 Status changed from not yet recruiting to recruiting.
- 23 May 2025 New trial record